Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 7/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | BRAF | P15056 | 4/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5336104 | 0.81 | CYP17A1 (0.41) | LMNAMAP4K4KDRTNNI3KMAPK14 | |
| SCHEMBL5451118 | 0.80 | MAP2K7 (0.51) | MAP4K4KDRTNNI3KMAPK14BRAF | |
| SCHEMBL5446984 | 0.78 | MAP4K4 (0.48) | MAP4K4KDRTNNI3KMAPK14BRAF | |
| SCHEMBL9909932 | 0.78 | LMNA (0.53) | LMNAMAP4K4MAPTCYP17A1ALDH1A1 | |
| SCHEMBL1162957 | 0.78 | GPR119 (0.50) | LMNAMAP4K4MAPK14GPR119MAPT | |
| SCHEMBL5319197 | 0.77 | KMO (0.52) | MAP4K4KDRTNNI3KMAPK14BRAF | |
| SCHEMBL5337202 | 0.76 | KDR (0.62) | KDRBRAF | |
| SCHEMBL22541668 | 0.76 | KDR (0.60) | MAP4K4KDRTNNI3KMAPK14BRAF | |
| SCHEMBL5319488 | 0.76 | MAP4K4 (0.46) | MAP4K4KDRTNNI3KMAPK14BRAF | |
| SCHEMBL14447591 | 0.76 | MAP4K4 (0.46) | MAP4K4KDRTNNI3KMAPK14BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | LMNA 4180/4885MAP4K4 69/4885KDR 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.